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Introduction:
In the United States, prostate cancer (PCa) remains the most common solid tumor malignancy in men, causing approximately 30,000 deaths in 2004 [1] . With the goal of trying to better understand the biology of prostate tumorigenesis and metastasis, we have developed a rapid autopsy program to collect tumors from multiple sites including solid organs and bone in order to perform molecular studies to better delineate PCa progression [2] . Our group has used these samples with a combination of cDNA expression and tissue microarray analysis approaches to identify novel PCa biomarkers, including EZH2, MTA1, PIMI, and AMACR using a supervised analysis comparing androgen independent to localized PCa samples [3] [4] [5] [6] [7] . As part of these studies we have begun to investigate the biology underlying the predisposition of prostate cancer to grow preferentially in osseous sites. We have isolated cell lines from bone and soft tissue sites, VCaP and DuCaP, and utilized these to investigate whether the gene expression of these cell lines gave us clues as to whether the prostate cancer cell "seed" demonstrated characteristics that would explain metastasis to bone versus soft tissue [8] [9] [10] [11] . We also investigated the characteristics of a small number of bone versus soft tissue metastases and found preliminary differences in their gene expression patterns. Our original statement of work and our subsequent interim reports have detailed our investigations.
These previous studies, however, lump metastastic tumors as a single entity, while the patterns of dissemination at autopsy suggest that metastatic cancer may better be characterized as a group of diseases rather than a single entity. Our goal over the last period of the grant was to study the phenotypic and genotypic characteristics of metastatic prostate cancer in detail. Our data demonstrate that metastatic prostate cancer demonstrates significant heterogeneity, even within the same patient. No consistent differences were found between bone and soft tissue sites that could explain the predilection of prostate cancer cells to metastasize to bone. This suggests that biologic differences leading to the predominant pattern of prostate cancer metastasis to bone may be related to the bone "soil" rather than the prostate cancer "seed". Metastatic hormone refractory PCa has a heterogeneous morphology, immunophenotype, and genotype, demonstrating that "metastatic disease" is a group of diseases even within the same patient. An appreciation of this heterogeneity is critical to evaluating diagnostic and prognostic biomarkers as well as designing therapeutic targets for advanced disease. Further investigation of the bone versus soft tissue stroma in cancer versus normal tissue is warranted. We believe detailed characterization of the heterogeneous phenotypic spectrum of end stage metastatic PCa will guide future molecular studies on metastatic disease, as well as provide a framework for identifying subtypes that may respond better to novel therapeutics. -4 Body:
Between September 1996 and November 2003, 30 rapid autopsies were performed on men who died of advanced hormone refractory PCa. The median age at time of death was 71 years (range 53-84 years). Twenty eight men were initially diagnosed with clinically localized prostate cancer but developed widely disseminated disease after 5-10 years. Eight men underwent radical prostatectomy before receiving additional treatment and seventeen men received external beam radiation as their primary treatment. Twenty-eight men received combination chemotherapy and all underwent hormonal manipulation. Initial Gleason score was documented in 20 of 30 men and ranged from 4 to 10. The time patients were treated with androgen deprivation ranged from 0 to 144 months. Patients survived in the hormone refractory state (measured as time from first chemotherapy) from 0 to 61 months with a hormone refractory median survival of 14.5 months. Widely disseminated PCa was found in most cases. Bone (83%) was the commonest site of metastasis, followed by liver (66%), lymph nodes (63%), lungs (50%), soft tissues (40%), dura (26%), and adrenal glands (23%). A summary of androgen therapy effect as has been previously described in primary PCa [12] . Residual tumor was identified in 20/21 cases, eight cases had extensive disease with involvement of bladder and pelvic soft tissues, while 12 had low volume of disease. Review of the histological appearance of these metastatic prostate cancers revealed heterogeneous patterns with architectural patterns similar to primary prostate cancers as described by Gleason [13] . Although Gleason grading in a clinical setting is not recommended for metastatic tumors, we nevertheless applied the Gleason grades in order to use a system that is well known to practicing pathologists [14] . Four cases had uniform tumor morphology at all sites, growing in solid sheets and nests with or without comedonecrosis, resembling Gleason grade 5 (Fig 2A-B) . Three cases demonstrated uniform morphology at all sites with tumors growing in a confluent cribriform glandular pattern resembling Gleason grade 4 (Fig 2Q) . The majority of cases (18 cases) had tumors with mixture of above two growth patterns resembling mixture of Gleason grades 4 and 5. Three cases demonstrated neuroendocrine (NE) differentiation characterized by tumor growing in nests, trabaculae and ribbons with uniform round nuclei, high N: C ratio and salt and pepper chromatin . Only 1 of these 3 cases was seen as pure growth pattern, while in remaining 2 cases NE differentiation was seen in combination with Gleason Fig 2H) and another case demonstrated focal signet ring cell differentiation (Fig 21) in addition to growth pattern of Gleason grade 5. The wide range of these histological patterns was not associated with a particular organ site.
A tissue microarray (TMA) was constructed from all 30 autopsies to represent all PCa metastasis sites and prostate (if present) [ 15] . Three cores (0.6 mm in diameter) were taken from each representative tissue block. This TMA was immunostained for a variety of tumor markers, including PSA, Androgen Receptor (AR), Chromogranin (CGA), Synaptophysin (SYN), cc-MethyAcylCoenzyme Racemase (AMACR), and the proliferation marker MIB-1. Immunohistochemistry (IHC) was performed using standard avidin-biotin complex protocol. For PSA, CGA, SYN, AMACR and MIB-1 antibodies, antigen retrieval was performed in citrate buffer, at pH 6.0 and for AR; antigen retrieval was performed using EDTA at pH 8.0 in a pressure cooker. The primary antibodies and dilution were as followings: Polyclonal PSA (Dako cytomation, Carpentaria, CA) 1:2000; Monoclonal AR-clone AR 441 (Neo Markers, Fremont, CA) 1:50, CGA (Biogenex, San Ramon, CA) 1:160; SYN (Biogenex, San Ramon, CA) 1:600; AMACR (generated from denatured recombinant antigen to AMACR) 1:5000, and MIB-1 (Dako corporation, Carpentaria, CA) 1:100. The slides were evaluated for adequacy using a standard bright field microscope. Digital images were then acquired using the BLISS Imaging System (Bacus Laboratory, Lombard, IL). Immunohistochemistry evaluation was carried out using Chromavision ACIS II version (Chromavision Medical Systems, Inc) [16] . The ACIS uses pre-programmed advanced color detection software that measures immunohistochemical stains intensity (range 0-255) and percentage expression (0-100%). Because the system has no means of distinguishing tumor tissue from non-cancerous tissue, all images were reviewed by one of the study pathologists. Tumor tissue was electronically circled on the computer screen and only those areas were used to measure the percentage of the circled cells staining positive for each of the tested markers (0-100%). The final data was recorded in a Microsoft Excel datasheet and used for statistical analysis.
The results are summarized in Table 1 Having demonstrated the marked variation of immunomarkers in different organ sites and patients, we next investigated the expression of AR and PSA in tissue sites within the same patient. Table 2 demonstrates the results for 4 different representative patients. Results are present as the median % staining. A range is given if there was more than one sample from that given site in a patient. All of the patients demonstrated marked differences in AR expression between different tissue sites (2-50 fold). There was no pattern to the differences in AR expression between the different organ sites that could be distinguished and this was true across all patients. Perhaps most striking was that several patients demonstrated a high amount of AR staining despite the fact that they were no longer responding to androgen deprivation therapy. PSA expression also varied widely between tissue sites and sometimes, even within the same tissue site of a patient. For example, Case # 30 demonstrated a range of PSA expression from median 3.03 in the prostate to a median of 60.61 in the bone, but the range of expression in the bone itself ranged from 14.67 -77.86. We next sought to determine if the heterogeneity in histology and phenotype was mirrored by heterogeneity in gene expression. Using expression array data that we have previously generated [6, 7] , we performed hierarchical clustering of the 16 metastatic samples from 6 cases in the rapid autopsy series. The metastatic adenocarcinoma samples were highly heterogenous (figure 3). Only two metastases from a patient with small cell histology demonstrated comparable cDNA expression results ( figure 3 ). Utilizing the Oncomine database, we found that these tumors exhibited a similar expression pattern as small cell lung cancer. We, as well as others, have identified several genes that are differentially expressed in primary versus metastatic disease [6, 7, 17] . By definition, these analyses are designed to find potential similarities between samples at a similar disease stage and compare the two groups. While these studies have identified several potential biomarkers, they were also remarkable for the amount of heterogeneity and overlap between primary and metastatic samples. To date, metastatic prostate tissue samples from the same patient and between patients have not been systematically been analyzed in an attempt to quantify this heterogeneity and determine if it may be important. Our data demonstrate that there are significant differences in the genotype and phenotype of metastatic prostate cancer between patients and within the same patient. There does not appear to be a correlation between bone and soft tissue sites in this extensive study as compared to our earlier preliminary data.
Stephen Paget first postulated a "seed" versus "soil" hypothesis to describe the metastatic process, believing that metastasis was dependent on both properties inherent in the cancer cell as well as the microenvironment of the metastatic site. The purpose of this grant was to explore the properties inherent in the cancer cells themselves by investigating the phenotypic and genotypic traits of metastatic prostate cancer from various sites as well as cell lines derived from various sites. Our data demonstrated differences in the ability to cells derived from bone metastases as compared to soft tissue metastases to adhere to bone derived endothelium. Our move to human tissues over the last grant period to investigate gene expression in detail has demonstrated no clear gene expression pattern that leads to bone versus soft tissue metastasis. This leads us to ask the next question which is what aspects of the target organ microenvironment are important for preferential metastasis. This will be the subject of future studies. 
1A:
Investigate the effects of known bone marrow cytokines on the growth of VCaP and DuCaP. We will investigate the effects of transferring, TGF-beta, OPG, OPN, OCN, BMPs, PDGF, bFGF, and other factors by measuring the effects of these cytokines on cell doubling time in a dose dependent manner (Months 1-12).
1B:
Investigate the effects of bone extracellular matrix components on the growth of VCaP versus DuCaP cells. We will investigate intact bone marrow matrix as well as individual components of the matrix including fibronectin, laminin, and collagen I by measuring the effects of these matrix components on cell doubling time in a dose dependent manner. These will then be done in combination with the important cytokines that modulate growth as determined in 1A (Months 13-24).
1C:
Investigate the adhesion of VCaP versus DuCaP to human bone marrow endothelium (HBME). We will investigate differential binding of the two prostate cancer cell lines to HBME. We will investigate whether cytokines, such as TGF-31, bFGF, IGF type I, JGF type II, EGF, IL-6, osteopontin, BMO 4, BMP 5, and BMP 6, also modulate their adhesion. We will investigate the effect of plating the HBME cells on various bone matrix components up or down regulate the adhesion of the two prostate cancer cell lines (Months 25-36).
Task 2. To investigate the differential gene expression of VCaP versus DuCaP cells by cDNA microarrays to identify specific gene products important in the metastasis of prostate cancer to bone.
2A:
Gene profiling. We will investigate the molecular profile of VCaP and DUCaP cells utilizing cDNA microarray technology. A 9,978 element human cDNA microarray composed of approximately 4000 known, named genes from the Research Genetics human cDNA clone set, 5000 ESTs, 500 control elements, and 500 specific cancer and apoptosis related genes will e utilized. In addition to VCaP and DuCaP, samples will be initially taken from the cell lines PC-3, DU 145, and LNCaP. Genes that are overexpressed or underexpressed will be confirmed by Northern analysis (Months 1-12).
2B:
Characterization of proteins. We will characterize known or unknown gene products that are differentially expressed between VCaP and DuCaP. Studies will be targeted to characterizing identified proteins by sequence analysis, genbank searches, antibody development, affinity chromatography, and subcecllular localization (Months 13-36).
Task 3. (NEW) Development of a preclinical model to study prostate cancer metastasis in SCID mice.
3A:
Transfection and testing of cell lines. VCaP and DuCaP cell lines will be stably transfected with a retroviral vector containing luciferase. These will then be injected intracardiac into SCID mice and the pattern of metastases will be tracked and documented (Months 12-24). 
4A:
We will investigate samples from 30 rapid autopsies of men who died of advanced prostate cancer by immunohistochemistry of tissue microarrays. Soft tissue and bone metastases between patients as well as from the same patient will be studied (<100 metastases). TMA's will be stained for expression of PSA, AR, chromagranin, and other markers. Preliminary gene expression studies between metastases will also be studied by microarrays The investigators are required to report to the IRBMED [1) planned changes in any aspect of the study, and do not implement any change without receiving approval, except to eliminate immediate hazard to subjects, [2] any serious or unexpected adverse events, and [3] any new information on the project that may adversely influence the risk/benefit ratio.
The investigators are responsible for applying to the IRBMED to receive Scheduled-Continuation Review and Approval of the project about eight weeks prior to the "Expiration Date of Project Approval" shown in the descriptivc paragraph. In case IRBMED approval is not secured prior to Expiration Date, subject recruitment activity will ceasc, and no research interventions will be administered to the research subjects except to eliminate immediate hazard.
A list of IRBMED members is available at The IRBMED Internet web site ("Membership Roster (IRBMED)"). This Notice of Outcome document and the membership roster may be submnited to sponsors of the research.
Note; If ihis research study will take place in the General Clinical Research Center (GCRC) please remember to send the GCRC a copy of all IRBMED approval loners and approved consent forms- Cancer (National Cancer Institute grant CA69568) and the Prostate Cancer genotype, demonstrating that "metastatic disease" is a group of diseases Foundation. Patients were identified with hormone-refractory prostate cancer even within the same patient. An appreciation of this heterogeneity is by the Medical Oncology Service of the Comprehensive Cancer Center at the critical to evaluating diagnostic and prognostic biomarkers as well as to University of Michigan Hospitals as described previously (2) . The clinical designing therapeutic targets for advanced disease, information obtained for each patient included age at diagnosis, age at death, months to death after diagnosis, initial Gleason score, time on hormonal INTRODUCTION therapy only, and type of primary and systemic therapy. These autopsies have been referred to as "rapid" or "warm" because of the short time interval
In the United States, prostate cancer remains the most common (average 3 hours) between patient death and starting the autopsy. solid tumor malignancy in men, causing -30,000 deaths in 2004 (1).
Pathology Data. Pathology data included detailed histologic evaluation of solid tumormalignancying mobette, cundersiang -30,0heas b i ny 24 (e prostate cancer at metastatic sites, location and systemic distribution pattern of With the goal of trying to better understand the biology of prostate metastasis at both osseous and nonosseous organ sites, and histology of the tumorigenesis and metastasis, we have developed a rapid autopsy prostate in event of no previous radical prostatectomy. Microscopic evaluation program to collect tumors from multiple sites including solid organs of all slides from each tumor site was evaluated by the study pathologists and bone to perform molecular studies to better delineate prostate (R. B. S., R. M., M. A. R.). cancer progression (2) . Our group has used these samples with a Construction of Tissue Microarray and Immunohistochemistry. A tiscombination of eDNA expression and tissue microarray analysis sue microarray was constructed from all 30 autopsies to represent all of the approaches to identify novel prostate cancer biomarkers, including prostate cancer metastasis sites and the prostate (if present). Three cores (0.6 Enhancer of Zeste homolog 2 (EZH2), Metastasis associated 1 mm in diameter) were taken from each representative tissue block. The tissue (MTA 1), PIM 1, and ei-methylacyl-CoA racemase (AMACR), with a microarray construction protocol has been described previously (8) (9) (10) . This supervised analysis comparing androgen-independent to localized tissue microarray was immunostained for a variety of tumor markers, including prostate cancer samples (3-7).
prostate-specific antigen (PSA), androgen receptor (AR), chromogranin prostate cnerious sa es, (3) (4) (5) (6) (7) l(CGA) , synaptophysin (SYN), a-methylacylCoA-racemase (AMACR), and the proliferation marker MIB-l. Immunohistochemistry was performed with single entity, whereas the patterns of dissemination at autopsy suggest standard avidin-biotin complex protocol. For PSA, CGA, SYN, AMACR and that metastatic cancer may better be characterized as a group of MIB-I antibodies, antigen retrieval was performed in citrate buffer at pH 6.0; diseases rather than a single entity. Our goal of the present study was and for AR, antigen retrieval was performed with EDTA at pH 8.0 in a to study the phenotypic characteristics of metastatic prostate cancer in pressure cooker. The primary antibodies and dilution were as followings: detail. Brain Adrenal the tested markers (0-100%). The final data were recorded in a Microsoft Dura Excel datasheet and were used for statistical analysis.
Microarray Analysis (cDNA). The spotted cDNA microarrays used for SoftTissue the identification of differentially expressed genes in the rapid autopsy series Lung have been previously described (6, 7) . The cDNA arrays contained -5,500 Lymph Node known, named genes from the Research Genetics human cDNA clone set, and >4,400 expressed sequence tags (7) . The expression array data were analyzed Liver with a Cluster and TreeViews to explore for relationships between samples Bone (14) . 0 10 similar to primary prostate cancers as described by Gleason (16) . sites, growing in solid sheets and nests with or without comedoneAlthough Gleason grading in a clinical setting is not recommended for crosis, resembling Gleason grade 5 ( Fig. 2A and B) . Three cases metastatic tumors (17), we nevertheless applied the Gleason grades to demonstrated uniform morphology at all sites, with tumors growing in use a system that is well known to practicing pathologists. The a confluent cribriform glandular pattern resembling Gleason grade 4 distribution and overlap of different histologic patterns identified in (Fig. 2C) . The majority of cases (18 cases) had tumors with a mixture these cases are schematically demonstrated in Fig. lB and summa-of the above two growth patterns resembling a mixture of Gleason rized in Table 2 . Four cases had uniform tumor morphology at all grades 4 and 5. Three cases demonstrated neuroendocrine differenti- 
PHENOTYPE OF ANDROGEN-INDEPENDENT PROSTATE CANCER
ation characterized by tumor growing in nests, trabaculae, and ribbons to 99.44; SEM, 34.5; Table 2 ; Fig. 3 ). Consistent with its role as a with uniform round nuclei, high N:C ratio, and salt and pepper transcription factor, AR was localized in nuclei. AR expression varied chromatin ( Fig. 2D and E) . Only one of these three cases was seen as across tumor samples with 31% (83 of 265) of tumor samples expure growth pattern, whereas in the remaining two cases, neuroendo-pressing >50% AR and 41.5% (100 of 265) expressing <10% AR. crine differentiation was seen in combination with Gleason grade 5 Overall expression of AR was down-regulated with median AR expattern. Two cases had tumors with small-cell neuroendocrine carci-pression of 20.04% (range, 0-100%, SEM, 34.28; Table 2 ; Fig. 3 ). noma, similar to oat-cell carcinoma of the lung, characterized by The intensity of AMACR expression varied among the metastatic spindling, crushing, and molding of the nuclei and high mitotic tumors; the median percentage of positive tumor cells was 8.18% activity (Fig. 2F) . Three cases had well-formed glands resembling (range, 0.19-71.97%; SEM, 14.58). The median MIB-1 expression Gleason grade 3 at some metastatic sites in addition to other growth was 4.55% (range, 0.25-26%; SEM, 4.61). CGA and SYN were patterns (three cases; Fig. 2G ). In one case, metastatic tumors dem-infrequently observed in these metastatic prostate cancer cases, as we onstrated poor cohesion with an undifferentiated growth pattern (Fig. have reported previously (8) . The median percentage of metastatic 2H), and another case demonstrated focal signet ring cell differentitumor cells demonstrating either CGA or SYN protein expression was ation (Fig. 21 ) in addition to growth pattern of Gleason grade 5. The 2.23% (range, 0.21-62.51; SEM, 7.55) and 0.83% (range, 0-49.11%; wide range of these varied histologic patterns is summarized and SEM, 8.21), respectively. Cases with neuroendocrine/small-cell morillustrated in Fig. 2 and Table 2 . The distribution and overlap of phology usually demonstrated neuroendocrine expression. We invesdifferent histologic patterns identified in these cases are schematically tigated whether any of the immunomarkers were predictive of survival demonstrated in Fig. lB . In one case, focal sarcomatoid differentiation time from the initiation of chemotherapy to death. Patients with a PSA was present only within the prostate site. Focal to diffuse nuclear median expression >50% demonstrated a significantly better survival pleomorphism within tumor cells was seen in 40% of cases, the than those with <50% expression (P < 0.03). remaining cases showed round-to-oval uniform nuclei often with
Immunophenotype of Prostate Cancer in the Same Patient. prominent nucleoli, a bland cytology typical of prostate cancer.
Having demonstrated the marked variation of immunomarkers in Choice of Immunomarkers. Previous work by our group and different organ sites and patients, we next investigated the expression others have described the immunophenotype of hormone-refractory of AR and PSA in tissue sites within the same patient. Tables 3 and metastatic prostate tumors (7, 8, (18) (19) (20) . One limitation of our pre-4 demonstrate the results for four different representative patients. vious work has been the subjective manner in which protein expres-Resultsare presents the mediaperentagestaing Aangs sion was reported. Therefore, to attempt to provide more quantitative Results aif resent as the median percentage staining. A range is results and to study potential heterogeneity, we used the Chroma given if there was more than one sample from that given site in a vision ACIS II system for the evaluation of several prostate cancer patient. All of the patients demonstrated marked differences in AR immunomarkers including PSA, AR, CGA, SYN, MIB-1, and AM-expression between different tissue sites (2-to 50-fold; Table 3 ). ACR. PSA was chosen because of its common use as a surrogate There was no pattern to the differences in AR expression between the marker in the treatment of metastatic disease. AR was chosen because different organ sites that could be distinguished, and this was true of its importance in understanding the development of androgen-across all patients. Perhaps most striking was that several patients independent disease. CGA and SYN were chosen to explore the demonstrated a high amount of AR staining, although they were no concept of neuroendocrine differentiation in androgen-independent longer responding to androgen-deprivation therapy. PSA expression disease. MIB-I was chosen as a proliferation marker. AMACR, a new also varied widely between tissue sites and, sometimes, even within molecular marker, has previously been shown to be a highly sensitive the same tissue site of a patient (Table 4) . For example, Case 30 marker for clinically localized prostate cancer and colorectal cancer demonstrated a range of PSA expression from a median of 3.03 in the (3, 21) . Our group recently demonstrated that AMACR expression prostate to a median of 60.61 in the bone, but the range of expression is down-regulated in hormone-refractory metastatic prostate cancer, in the bone itself ranged from 14.67 to 77.86. is androgen independent, and is likely related to tumor differentiaExpression Array Analysis of Different Metastatic Tissues. We tion (22) . next sought to determine whether the heterogeneity in histology and Immunophenotype of Prostate Cancer in Different Patients. phenotype was mirrored by heterogeneity in gene expression. With The results are summarized in Table 2 . The data present the median expression array data that we have previously generated (6) (7) (8) , we percentage staining with the range of the immunomarkers across all performed hierarchical clustering of the 16 metastatic samples from patients according to tissue site as present on the tissue microarray.
six cases in the rapid autopsy series. The metastatic adenocarcinoma All of the immunomarkers demonstrated considerable heterogeneity samples were highly heterogeneous (Fig. 4) . Only two metastases across disease sites. PSA expression was seen to vary for the percent-from a patient with small-cell histology demonstrated comparable age of PSA-positive cells with median expression of 39.3 (range, 0.3 cDNA expression results (Fig. 4) found that these tumors exhibited a similar expression pattern as patients have not been systematically been analyzed in an attempt to small-cell lung cancer (23).
quantify this heterogeneity and to determine whether it may be important. Our data demonstrate that there are substantial differences in DISCUSSION the genotype and phenotype of metastatic prostate cancer between patients and within the same patient. The data in Tables 2, 3 , and 4, Autopsy series have been a valuable part of understanding the as well as in Fig. 3 demonstrate this heterogeneity when comparing natural history of diseases, including prostate cancer (24-29). This metastatic sites. We did not investigate heterogeneity within individstudy underscores the continued importance of the autopsy in modem ual metastatic sites by comparing multiple biopsies from a given site; medicine. It demonstrates that metastatic cancer is a group of diseases however, it seems likely that heterogeneity would have been revealed and needs to be treated as such and emphasizes the importance of at that level also. This will be the subject of future studies. obtaining metastatic tissue to understand the biology of prostate Normal prostate tissue and virtually all primary prostate cancer cancer. It is a widespread belief that prostate cancer metastasizes to have been found to uniformly express AR; however, information of osseous sites but rarely to visceral organs. Three groups (i.e., Univer-AR expression in hormone-refractory prostate cancer is limited (33). sity of Michigan, Ann Arbor, MI; University of Washington, Seattle, Our study demonstrates heterogeneity in AR expression with frequent Washington; and Johns Hopkins University, Baltimore, Maryland) AR-positive and AR-negative tumor populations between and within have developed rapid autopsy programs with the goal of procuring the same patient (Tables 2 and 3 ). In this study, overall AR expression metastatic osseous and nonosseous prostate cancer samples for re-is down-regulated in hormone-refractory prostate cancer, with 41.5% search purposes (2, 20) . Our data and those of others demonstrate that of tumor samples demonstrating <e10% of AR, which suggests that, in prostate cancer commonly metastasizes to lymph nodes, liver, lung, such ses dernate A 10% of may also be tat adrenal, and dura sites in addition to the bone (20, 24). The MIB-1 such casesian alter n ARdypas dents may a owbe tan data confirm the work of others in demonstrating the slow doubling in th pr ei en independence owevR the time of prostate cancer, which suggests that the cancer develops in majority of patients still express substantial amounts of AR although multiple sites over a long period of time (30, 31) . These data also have they have undergone long-term androgen ablation. Because intracelimplications for developing therapy because treatment based on using lular AR, a ligand-dependent transcription activator mediates androagents that act on cells with a rapid doubling time may not be effective gen action, abnormalities in AR are believed to play an important role in androgen-independent prostate cancer. The low rate of effective-in the progression of prostate cancer (34) (35) (36) . Chen et al. (37) have ness of traditional chemotherapy agents in prostate cancer appears to recently demonstrated that the AR in androgen-independent prostate reflect this finding, cancer can still be active and fueled by submicromolar amount of We, as well as others, have identified several genes that are differ-testosterone. Our present study supports the observation that the AR entially expressed in primary versus metastatic disease (6, 7, 32) . By still may play a central role in the biology of what has been traditiondefinition, these analyses are designed to find potential similarities ally termed "androgen-independent" disease. between samples at a similar disease stage and compare the two Another clinically significant finding of this study is the low groups. Whereas these studies have identified several potential bi-frequency of neuroendocrine phenotype in prostate cancer patients. It omarkers, they were also remarkable for the amount of heterogeneity has been suggested that most androgen-independent prostate cancer and overlap between primary and metastatic samples. To date, met-has a neuroendocrine phenotype, and investigators have reported a astatic prostate tissue samples from the same patient and between correlation between the percentage of neuroendocrine expression with (8, 20, 38, 39) . Our data, not correlate with clinical outcome in the androgen-independent paas well as those of others, especially from the University of Washtients (as measured from the time of first chemotherapy). ington, Seattle, suggest that this is not the case (20). In our series, only
We have extensively used these tumor samples from the rapid three patients demonstrated neuroendocrine phenotype by histology autopsy for research directed at understanding prostate cancer pro-(two with pure small-cell histology and one with pure neuroendocrine gression. Initial expression array analysis was critical in the identifidifferentiation but not reaching the threshold of small-cell carcinoma), cation of prostate-and cancer-specific genes such as Hepsin, EZH2, Immunostaining for SYN and CGA was considerably variable and did MTAI, and TPD52. (6, 7, 40) This initial work grouped all of the 9214 PHENOTYPE OF ANDROGEN-INDEPENDENT PROSTATE CANCER hormone-refractory metastatic prostate cancer samples together for Srilakshmi Bhagavathula for assistance in preparation of the database; and Dr. purposes of analysis and compared them with primary cancers as well Lakshmi Priya Kunju for her participation in the performance of rapid autopsy as with normal tissue. These analyses were valuable in that they cases. picked out dominant genes that were expressed differently over a majority of different tumor stages; however, these studies were not done by laser-capture microdissection and, therefore, did not take into REFERENCES account the heterogeneity of the tissues at similar stages. small-cell metastatic samples (Fig. 4) . When small-cell prostate can-10:15-20. cer does occur, it seems to have the genotypic pattern of small-cell 12 PLOD2, TOP2A, Cyclin A2, CDC2, RBBP8, and GNAS, found to be 6:3552-9. overexpressed in the two samples from a metastatic small-cell cancer 14 biomarkers has yet been identified that can successfully predict dis-25. Billis A. Latent carcinoma and atypical lesions of prostate. An autopsy study. Urology ease recurrence 100% of the time. Although studies have tried to 1986;28:324-9. 26 . Gatling RR. Prostate carcinoma: an autopsy evaluation of the influence of age, tumor identify subsets of genes that characterize the metastatic phenotype, grade, and therapy on tumor biology. South Med 1 1990; 83:782-4. these, by definition, ignore the heterogeneity of metastatic cancer (6, 27 . Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an 7, 32). We demonstrate that end-stage hormone-refractory metastatic autopsy study of 249 cases. In Vivo 1994; 8:439-43. prostate cancer is a heterogeneous group of diseases. Understanding 28. Stemmermann GN, Nomura AM, Chyou PH, Yatani R. A prospective comparison of this heterogeneity is key to understanding prostate cancer progression prostate cancer at autopsy and as a clinical event: the Hawaii Japanese experience. Cancer Epidemiol Biomark Prev 1992; 1:189-93. and to guiding the development of future treatment paradigms. 
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Prostate cancer is the second most common from 60 of 126 (54%) patients with localized cause of cancer-related deaths among men in prostate cancer before radical prostatectomy, the United States [Jemal et al., 2003] . It is estiwhile only 33 of 138 (24%) patients had demated that 220,900 new cases will be diagnosed tectable PSA-expressing epithelial cells in perand 28,900 deaths will occur in 2003. Approxiipheral blood. This finding supports the mately 90% of advanced stage prostate cancer preferential enrichment of cancer cells in the patients develop bone lesions causing morbidity bone marrow as an early metastatic event and that includes bone pain, immobility, hematoleads to many interesting questions pertinent to poietic compromises, and spinal cord compresprostate cancer metastasis. How do the cancer sion [Bubendorf et al., 2000; Rubin et al., 2000] . cells outgrow and escape from the primary site? Current treatments are not curative, and paHow do they survive shear forces present in the tients have a median survival time of 9-circulation and evade immunosurveillance? 12 months after becoming hormone refractory How do these cells interact with the target bone [Cheville et al., 2002] .
endothelium? What factors in the bone microEllis et al. [2003] reported that prostateenvironment attract prostate cancer cells and specific antigen-(PSA-) expressing epithelial prompt them to initiate growth? Understanding cells were detected in bone marrow samples the biological processes leading to the establishment of clinically relevant bone metastases is not just an intellectual exercise as the answers to these questions may lead to invaluable therapeutic strategies to treat the currently incur- Fig. 1 . Steps in prostate cancer metastasis to bone. Successful metastasis is a multi-step process that includes (1) growth and escape from a primary organ, (2) intravasation, (3) survival in circulation, (4) chemoattraction and extravasation, (5) and growth in bone through (6) cross-talks with osteoblasts and osteoclasts. These steps require the ability of cancer cells to adhere to and migrate across the surrounding extracellular matrix (ECM), actions mediated by the integrins.
genesis, intravasation into and survival in cirof cancer showed that only 2% of cancer cells culation, attachment to a distant target organ, formed micrometastases [Luzzi et al., 1998 ; extravasation at that site, and growth of a Varghese et al.,2002] . Furthermore, 99% of these secondary neoplasm and, as such, appears to be micrometastases failed to form larger tumors, an inefficient process (Fig. 1) . While organalthoughnumeroussolitarycellsremaineddetecspecific localization of luciferase-labeled PCtable in the tissue months after injection [Nau-3 human prostate cancer cell line cells was mov et al., 2001 MacDonald et al., 20021 . visualized by non-invasive imaging 15 min postStephen Paget [1889] was the first to present intracardiac injection in immunocompromised an explanation for the non-random patterns of mice, no viable cells were detected 24 h later, cancer metastases. His "seed and soil" theory Despite this indication that most of the injected proposed that there was something about mecells were either dead or metabolically inactive, tastatic sites that promoted cancer cell growth skeletal and soft tissue micrometastases were similar to the tendency of seeds to grow in apparent on imaging several days later and fertile soil, i.e., that factors in the environment were confirmed histologically and radiographiat a metastatic site contributed to the prolifecally weeks later [Rosol et al., 2003] . Similarly, ration of cancer cells there. Forty years later, intravital videomicroscopy of various types James Ewing [1928] presented a different view
proposing that cancer cells grew at a particular site because they were directed to that site by the direction of blood flow and lymphatics. It is likely that both of these theories are correct, at least in part. Ewing's theory accounts for cancer growth in the draining lymph nodes and the liver, but Paget's theory describes distal metastases that are organ-specific, such as metastases to the bone. Isaiah Fidler [2002] redefined the modern "seed and soil" hypothesis as three principles.
First, cancerous tissues contained heterogeneous subpopulations of cells with different angiogenic, invasive, and metastatic properties. graph, after 3 days cells exhibiting diverse the surrounding stroma include numerous cell phenotypes are attached to the bone. We hytypes, such as fibroblast, endothelial, neuroenpothesize that these variable morphologies may docrine, and inflammatory cells; soluble growth represent the heterogeneous population of factors; and insoluble laminin-rich extracelluprostate cancer cells that differentially reslar matrix (ECM). Many of the steps in cancer ponds to growth on bone. Alternatively, these metastasis involve changes in cell adhesion to pleomorphic cells may be in different stages of adjacent cells and to the ECM. The cell surface metastasis, as some appear anchored to the receptor integrins have been implicated in bone at the extended edges, perhaps "feeling" these events since they mediate homotypic and out the environment for chemotactic factors, heterotypic interactions of prostate cancer cells while others seem to have formed firm adhewithin their microenvironment. Integrins are sions with the bone, suggesting that they may composed of non-covalently associated a and P have begun an invasive process.
subunits that play a role in mediating both cellcell interaction and cell-matrix interaction METASTATIC PROCESS AND INTEGRINS (Fig. 3) . To date, genes for 16 a and 8 0 subunits have been identified. Both types of subunits In normal prostate development, the interacencode single-pass transmembrane proteins tion of prostate epithelial cells with surroundwith short cytoplasmic tails, except for the P34 ing stroma influences their growth, survival, subunit which contains more than 100 residues and differentiation potential. Components of [Longhurst and Jennings, 1998; Mizejewski, [Argraves et al., 1987] .
sion and leads to an increase in cell adhesion to ECM proteins [Shen and Falzon, 2003 ].
The influence of integrin cell surface expression and interaction with the ECM in early Changes in integrin expression have been prostate cancer progression is also illustrated documented in primary prostate tumors and by prostate acinar morphogenesis using a series prostate cancer cell lines compared to normal of human prostatic epithelial cell lines. Nonprostate tissue (see Table I ). Immunohistumorigenic RWPE-1 prostate epithelial cell tochemical studies of normal, prostatic intraeline form acini when grown in three-dimenpithelial neoplasia (PIN), and cancerous sional Matrigel cell cultures, while invasive prostate tissues indicate that loss of the laminin WPE1-NB26 cells fail to form acini. In addition, receptor a604 integrins occurs with increasing RWPE-1 cells form acini on laminin-1, but not malignancy [Davis et al., 2001 ]. Low Gleason collagen or fibronectin, and are unable to form sum score correlates with increased expression these structures when exposed to blocking of the a3 and a6 integrin subunits, while high antibodies for laminin-1 and laminin integrin Gleason sum score correlates with low expres- [Passaniti et al., 1992] . Secretion of proteolytic enzymes by prostate cancer cells Hemodynamics may bring cancer cells into permits the cells to digest through the basement the bone marrow, but it alone does not explain membrane to reach the microvasculature.
the high frequency of prostate cancer metastaLaminin-5 is a crucial protein in mediating cell sis to the bone [Yoneda, 1998] . Perhaps the stability, migration, and anchoring filament presence of chemotactic gradients in the bone formation. Invasive prostate carcinoma shows sinusoids contributes to the attraction, but a lack of protein expression of P3 and y2 chains the role cell-cell interaction plays cannot be of laminin-5 and altered expression of the a3 ignored. We have shown that prostate cancer chain [Hao et al., 20011 [Cooper et al., 2000b] . ing stroma, they enter the microvasculature in a Adhesion and extravasation of prostate canprocess called intravasation and must evade cer cells from fenestrated bone marrow endotheassault by the immune system and the simple lium most likely occurs as a complex set of shear forces of blood flow. Cells appear to travel interactions between bone marrow endothelial through the blood as part of a fibrin clot surcells, bone ECM components, and bone marrow rounded by other cancer cells and platelets to stromal cells. The "dock and lock" mechanism survive [Walz and Fenton, 1994] , with platelets was proposed as one explanation for extravasabinding to cancer cells via the integrins aIIbtion and is similar to the inflammatory response IIIa. Treatment with either anti-platelet antiof leukocytes [Honn and Tang, 1992] as both bodies or heparin inhibits platelet-tumor cell processes involve the arrest of circulating cells interaction [Borsig et al., 2001] and reduces on the endothelium by low-affinity binding, lung metastasis [Stoelcker et al., 1996] . Simiinduction of a firmer cell adhesion, extravasalarly, blocking antibodies to aIIibIIIa inhibits tion, and invasion of the surrounding matrix lung colonization of mouse tail vein-injected [Buck, 1995] . During the "docking" step of DU145 cells [Trikha et al., 1998] .
inflammatory response, induced expression of In the vasculature, thrombin may mediate P-selectin, a type of cell adhesion molecule on cancer cell-platelet adhesion [Cooper et al., platelets, leukocytes, and endothelial cells, on 2003] and may activate resting platelet integactivated endothelial cells is responsible for the rins cIIb0IIIa to induce platelet aggregation low affinity binding of leukocytes to endothelial [Trikha and Nakada, 2002] . As well, activacells [Meyer and Hart, 1998 ]. Similarly, intertion of protease-activated receptor 1 (PAR1) on action of P-selectin with its ligand sialyl Lewisx cancer cells by thrombin increases cell adhesion carbohydrates is believed to cause the arrest of to platelets [Walz and Fenton, 1994] slower tumor growth occur when colon cancer cells are implanted into P-selectin-deficient cancer cell "seeds" [Paget, 18891. For example, mice [Kim et al., 1998 ]. In breast and prostate bone extracts induce at least a three-fold cancer cells, adhesion to the microvascular increase in invasion by PC-3 and DU145 cells endothelium of metastasis-prone tissues is also compared with brain and other tissue extracts, mediated in part by interactions between demonstrating that bone contains significant cancer-associated Thomsen-Friedenreich (TF) migration and chemoinvasion promoting facglycoantigen (Galol-3GalNAc) presenting on tors for prostate cancer cells [Jacob et al., 1999] . neoplastic cells and P-galactoside binding lectin By purifying the bone extract, osteonectin was galectin-3 expressing on endothelium [Lehr and identified as the chemoattractant that promo- Pienta, 1998; Ellerhorst et al., 1999; ted prostate cancer cell invasion [Jacob et al., et al., 2000 [Jacob et al., et al., , 2001 Nangia-Makker et al., 2002; 1999] . Blocking antibodies to the avJ3 integrins Khaldoyanidi et al., 2003 ]. This adhesion is have been shown to reduce prostate cancer cell abrogated by blocking antibodies to 3-galactoadhesion to crude bone protein extract by 94% side-binding lectin, galectin -3, or TF antigen [Hullinger et al., 1998 ], suggesting the impor-[Lehr and Pienta, 1998; Glinsky et al., 2003] .
tance of the integrins in the process. Similar to inflammatory response of leukoNumerous other factors contribute to proscytes, the "locking" of prostate cancer cells to tate cancer cell proliferation in the bone, and endothelial cells is facilitated through the commany are mediated through the engagement of plex collaboration of integrins. We have preintegrin receptors. Unlike prostate epithelial viously reported that P1 integrin was not associated ECM, the main component of bone involved in PC-3 prostate cancer cell-endothe-ECM is collagen type I which is a ligand for a2p1 lial cell adhesion [Cooper et al., 2000a] . Howand a301 integrins. Greater proliferation rates ever, a more recent study showed that blocking for prostate cancer cells are observed in cells antibodies to this subunit inhibited adhesion of grown on collagen I compared to plastic or fibro-PC-3 cells to bone marrow endothelial cells by nectin substrates; cell signaling through phos-64% [Scott et al., 2001] . These conflicting results phatidylinositol 3-kinase (P13K) and increased suggest the involvement of other integrins or expression of cyclin D1 are implicated in this cell adhesion molecules in prostate cancer cell process [Kiefer and Farach-Carson, 2001 ]. adhesion to the endothelium. Indeed, cooperaInterestingly, osteopontin, a non-collagenous tivity between avP3, c55ol and a301 integrins is bone ECM component, stimulates proliferation necessary for PC-3 and DU145 cell adhesion to of quiescent prostate epithelial cells more than interleukin-1-stimulated human umbilical vein collagen in an integrin-mediated manner [Elgaendothelial cells [Romanov and Goligorsky, vish et al., 1998] Although more than 95% of the bone ECM is survive and propagate. In a review of bone scans composed of collagen type I, other proteins are from 27 patients with limited skeletal involvealso deposited by osteoblasts during bone forment, the distribution pattern of early prostate mation [Hauschka et al., 1986] . Co-culture of cancer metastases was similar to the distribu-PC-3 cells with osteoblasts reveals that transtion of normal adult bone marrow [Imbriaco forming growth factor-P1 (TGF-0) produced by et al., 1998 ]. This observation supports Ewing's osteoblasts stimulates PC-3 cell migration and theory that cancer cell delivery to the bone is invasion as well as increases a2pl and 030l simply a reflection of the volume of blood flow integrins expressions [Festuccia et al., 1999a] . [Ewing, 1928] . However, theories of preferenFurthermore, osteoblast-conditioned medium tial adhesion and the potential role of chemostimulates the release of proteolytic enzymes attractants in colonization and subsequent urokinase plasminogen activator and matrix growth are not discounted [Keller et al., 2001;  metalloproteinase-9 from prostate cancer cells Taichman et al., 2002; as [Festuccia et al., 1999b] . there is little doubt that the bone microenvironAlthough factors in the bone microenvironment provides a rich "soil" for the prostate ment promote prostate cancer cell growth, prostate cancer cells also contribute to bone of FAK compared to the poorly tumorigenic remodeling in a "vicious cycle" [Chung, 2003] .
LNCaP cells, suggesting a differential modulaBecause prostate cancer metastases are usually tion of the integrin signaling pathway in osteoblastic in nature, the role of bone morphometastatic prostate cancer cells [Slack et al., genetic proteins (BMPs) in the course of bone 2001]. metastasis is quite intriguing since they conCell motility are a coordination of focal tribute to bone formation. Bentley et al. [1992] adhesion assembly at the leading edge of motile first reported that the expression of BMP-6, a cells, providing traction for cell migration, and member of the TGF-P superfamily, was detected focal adhesion disassembly at the trailing edge in prostate tissue samples of over 50% of of these cells, resulting in forward movement patients with clinically defined metastatic pros- [Sastry and Burridge, 2000] . RhoGTPases, tate cancer, but not non-metastatic or benign activated through integrin-mediated, focal prostate samples. Subsequent studies have adhesion-localized FAK and other tyrosine confirmed the increased expression of BMP-6 kinases, and G-protein receptors, appear to be in metastatic prostate cancer cells [Barnes et al., key facilitators of these dynamics. These pro-1995; Hamdy et al., 1997; Autzen et al., 1998;  teins and their associated downstream signals Thomas and Hamdy, 2000] As discussed above, many steps of the metain cancer metastasis. Activated Rac coordinates static cascade involve the establishment and focal adhesion assembly in lamellipodium and termination of adhesive interactions between membrane ruffling [Ridley et al., 1992 ; Nobes cancer cells and the ECM via integrins. Howand Hall, 1995; Clark et al., 1998 ]. These new ever, integrins also regulate intracellular focal adhesions establish a path for cancer cells signaling pathways that control cytoskeletal to begin their quest to find more enriched "soil." organization, force generation, and survival Activated Rho generates contractile forces that [Hood and Cheresh, 2002] . This signal transpush a cell body toward the leading edge and can duction is modulated in two directions: activastimulate other downstream signaling pathtion of integrins to bind to ligands produces ways leading to stress fiber formation, cell "inside-out" signaling and generation of ligand contraction, or actin polymerization depending bound integrins activates downstream intracelon cross-talk between Rac, Cdc42, and other lular kinases and GTPases causing "outside-in" Rho regulatory proteins [Ridley, 2001] . For signaling. In this "outside-in" signaling, ligand example, inhibition of Rho kinase, a Rho downbound integrins cluster with structural and stream target, decreases prostate cancer cell catalytic focal adhesion-associated proteins at chemotactic migration in vitro and tumor cell-ECM junctions called focal adhesions.
growth and angiogenesis in vivo [Somlyo et al., Because integrins do not possess kinase activ-2000 . As well, a putative Rho regulatory ity, the focal adhesion-associated protein FAK protein was recently identified that encodes initiates the intracellular signaling cascade a novel Src homology 3 domain-containing using its ability to recruit downstream effectors guanine nucleotide exchange factor (CSGEF) to the focal adhesion [Hood and Cheresh, 2002] .
[ Qi et al., 2003] . Expressed only in prostate In prostate cancer, the highly tumorigenic PC-3 and liver tissues, CSGEF mRNA levels are inand DU145 cell lines have increased expression creased two-fold in the LNCaP prostate cancer cell line after androgen treatment, suggesting in" signaling pathway. Growth factors and a possible role of CSGEF in modulating prossignaling through the G-protein-coupled receptate cancer cell metastasis. G-protein receptor tors have been known to activate RhoGTPases PAR1 activation of Rho similarly induces (reviewed in [Kjoller and Hall, 19991) . Which actin cytoskeletal reorganization (reviewed in factor(s) in the microenvironments of the pri- [Whitehead et al., 2001] ). In prostate cancer mary tumor, the circulation, and the target cells, this activation contributes to increased organ can activate integrin-mediated adhesion, prostate cancer invasiveness [Chay et al., 2002;  dynamic cell structure, migration, and inva- Greenberg et al., 2003] and sion? The answers to these questions will lead increased production of stress fibers in LNCaP not only to a better understanding of the biology cells treated with thrombin [Greenberg et al., of prostate cancer metastasis but should also 2003].
lead to the identification of therapeutic targets for the prevention ant treatment of prostate PROSPECT: CAN INTEGRINS BE USED cancer metastasis.
AS TARGETS TO PREVENT OR TREAT BONE METASTASES?
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